Search clinical trials for: ATx201 Placebo

Total 53631 results

Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Pompe Disease Infantile-Onset

Taiwan, United States, Italy
AlgoTherapeutix

Recruiting

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (ACT)

Chemotherapy-induced Peripheral Neuropathy

United States, Spain, Belgium, France, Czechia, Poland, Italy
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Atopix Therapeutics, Ltd.
Simbec Research

Completed

First in Man Evaluation of Single and Multiple Doses of Oral ATX2417

Allergy

United Kingdom
Seaside Therapeutics, Inc.

Completed

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (Harbor-A)

Fragile X Syndrome

United States
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
AnnJi Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Spinal and Bulbar Muscular Atrophy | Kennedy's Disease

United States
UNION therapeutics

Completed

Evaluation of ATx201 as a Topical Antibiotic Agent

Infection, Bacterial

Austria
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
AlphaVax, Inc.

Completed

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) (CMV)

Cytomegalovirus Infections

United States
Timothy Roberts
Simons Foundation; Clinical Research Associates, LLC

Completed

MEG Study of Acute STX209 Effects in ASD

Autism Disorder

United States
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of Long COVID

Post Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19

United States
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

HIV Infections

United States, Botswana, South Africa
AlphaVax, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine...

Completed

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

HIV Infections

United States, South Africa
9 Meters Biopharma, Inc.

Completed

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Celiac Disease

Canada, United States
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Dravet Syndrome

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (ENDEAVOR)

Dravet Syndrome

United States
Coeptis Therapeutics
Fred Hutchinson Cancer Center

Completed

Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

COVID-19 Pneumonia

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
Seaside Therapeutics, Inc.

Completed

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

Fragile X Syndrome

United States
Amicus Therapeutics

Terminated

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Type 1 Gaucher Disease

United States, United Kingdom
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (UK Only)

Dravet Syndrome

United Kingdom
Xilio Development, Inc.

Recruiting

XTX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Almac Discovery

Terminated

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Ovarian Cancer | Solid Tumors

United Kingdom
Seaside Therapeutics, Inc.

Completed

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Fragile X Syndrome

United States
Aestus Therapeutics
National Institute of Neurological Disorders and Stroke (NINDS); Symbiance,... and other collaborators

Completed

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

Postherpetic Neuralgia

United States
PhytoTech Therapeutics, Ltd.

Unknown

Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms

Multiple Sclerosis

Israel
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
Alexion Pharmaceuticals

Completed

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Wilson Disease

United States, Germany, Austria, Poland, United Kingdom
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
Seaside Therapeutics, Inc.

Terminated

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Amicus Therapeutics

Completed

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Fabry Disease

United States, Italy, Spain, Turkey, Brazil, Canada, United Kingdom, France, Poland, Australia, Egypt, Argentina, Denmark
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more

3

Subscribe